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Phenobarbital has been in clinical use for over a century; phenytoin
for more than three-quarters of a century, and volatile anes-
thetics, such as isoflurane and halothane for more than half a
century. Despite the long history of use of these compounds for
the treatment of epilepsy, and for anesthesia, their effects on brain
development are still relatively poorly understood. For this reason,
the use of neuroactive drugs during gestation and infancy remains
one of the thorniest issues in clinical neurology and neonatology.
I had the privilege of co-editing this research topic with my
mentor, colleague, and friend, Dr. Karen Gale. Dr. Gale passed
away in August of 2014. She and I saw this research topic as an
opportunity to highlight the state of the field, and in particular,
underscore important future research directions. Together, these
articles do exactly that.
In this research topic, the current state of the field is reviewed
from pre-clinical and clinical perspectives by Turski and Ikonomi-
dou (1) and Gedzelman and Meador (2). These reviews highlight
converging results from animal and human studies that underscore
the profound impact of these drugs can have on the developing
brain. Complementing these reviews, Rochelle Caplan’s transla-
tional review focuses on the role of antiepileptic drugs in psy-
chopathology seen in pediatric epilepsy (3). From a translational
perspective, the review by Khanna and colleagues (4), and the
opinion piece by Pressler and Auvin (5) highlight the importance
of neuronal chloride homeostasis as a key regulator of neuronal
activity during brain development and as a critical mediator of
the efficacy of the first-line therapies for neonatal seizures (i.e.,
phenobarbital).
With respect to anesthesia, the review from Jevtovic-Todorovic
and colleagues (6) approaches the problem of anesthesia-induced
damage to the developing brain from a highly mechanistic per-
spective. In particular, they highlight the role of sub cellu-
lar organelles, such as mitochondia, in the pathophysiology of
neonatal anesthesia exposure. Furthermore, the review by Cheng
Wang outlines research approaches and models that have been
employed in pre-clinical pediatric neurotoxicology experiments
(7). Finally, the research article by Murphy and Baxter high-
lights sex-dependent effects of neonatal anesthesia exposure on
long-term cognitive outcomes (8).
In the decade and a half since the first characterization of
apoptotic neurodegeneration in the developing rat brain after
exposure to these drugs (9–11), this field has made considerable
advances in understanding mechanisms of toxicity and charac-
terizing the types of lasting injury that occur after early drug
exposure.
Indeed, the importance of this research was highlighted in the
2014 NINDS Benchmarks for Epilepsy Research, which lists as a
goal,“[To] identify the impact of pharmacological treatment of the
epilepsies on fetal and neonatal development. Develop strategies
to control seizures in pregnancy without causing harm to either
the mother or child” (12).
There are, however, many questions that remain to be
addressed.
1. To what degree do the mechanisms of developmental neurotox-
icity overlap and differ between classes of drugs (e.g., anesthesia
vs. antiepileptic drugs).
2. How can pre-clinical research influence clinical practice with
respect to these drugs?
3. What therapeutic strategies and adjunct treatments can be used
to minimize/avoid developmental neurotoxicity?
4. How does sex modulate risk for developmental neurotoxicity?
5. What features and types of toxicity will be revealed by studies
in non-human primate models?
It is my sincere hope that 10 years from now, we will have made
considerable progress in addressing these issues.
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